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This article describes the data obtained by the 
Portuguese Laboratory Network, reactivated follow-
ing the World Health Organization declaration of the 
2009 influenza pandemic, on the diagnoses of influ-
enza A(H1N1)pdm09 infection during the pandemic 
(2009/10) and post-pandemic (2010/11) influenza sea-
sons. The laboratories analysed and reported cases of 
influenza-like illness (ILI) and severe acute respiratory 
infection (SARI) to the National Influenza Reference 
Laboratory, which performed more detailed antigenic 
and genetic characterisation of the virus isolates. 
In 2009/10, a total of 62,089 ILI cases, distributed 
in two peaks, were analysed, 25,985 of which were 
positive for influenza A(H1N1)pdm09. Children aged 
5–14 years were the most affected. Viruses were both 
antigenically and genetically similar to the pandemic 
strain A/California/7/2009, included in the 2009/10 
pandemic vaccine. During the post-pandemic sea-
son, 1,496 ILI cases were tested for influenza A(H1N1)
pdm09, 572 of which were positive. Infection was 
mainly diagnosed in adolescent and adults. Although 
the 2010/11 viruses remained antigenically similar to 
A/California/7/2009, increased genetic variation was 
observed. During the two seasons, two viruses with 
the neuraminidase H275Y amino acid substitution, 
associated with oseltamivir resistance, were detected. 
The Laboratory Network made an important contribu-
tion to the description of the influenza activity in the 
two seasons.
Introduction
Although epidemics of influenza occur almost every 
year in temperate climates, the rates and severity of 
illness can vary substantially between seasons [1]. 
Every winter season influenza infection is associated 
with a considerable number of fatal cases especially in 
elderly people with chronic diseases [2]. Recent stud-
ies from different countries, including Portugal [3,4], 
estimate that 90% of excess deaths due to seasonal 
influenza occur in the elderly (≥65 years) who are at 
higher risk due to comorbidities. In Portugal, the sea-
sons with higher excess mortality were associated with 
the predominant circulation of influenza A(H3) viruses, 
while predominant circulation of type B viruses had a 
lower impact in mortality [4].
In March 2009 a new influenza virus circulating in 
humans emerged in Mexico. The new influenza A(H1N1)
pdm09, as it was later called, started disseminating 
throughout the world, giving rise to the first influenza 
pandemic of the 21st century, and appears to have 
been introduced in Europe by travellers returning from 
Mexico and by their contacts. Following the detection 
of the initial imported cases, there was a spring and 
summer wave of transmission which affected several 
European countries. Transmission accelerated again 
after the re-opening of schools, this time affecting all 
countries, and lead to an early autumn/winter wave [5].
Since 1990 and until the 2009/10 winter season, influ-
enza surveillance in Portugal had been carried out 
in the context of a National Influenza Surveillance 
Programme, coordinated by the National Influenza 
Reference Laboratory in cooperation with the 
Department of Epidemiology of the National Institute 
of Health and the General-Directorate of Health [6]. 
Activities within the Programme included collect-
ing, analysing and reporting clinical, epidemiologi-
cal and virological data on influenza-like illness (ILI), 
integrated from a sentinel network of general prac-
titioners and a non-sentinel network of emergency 
units located at hospitals and health centres from the 
National Health System. As it was well established, the 
Programme proved essential for monitoring the pan-
demic in Portugal [7], particularly in the pre-pandemic 
phases when all suspected cases were referred to ref-
erence hospitals and the laboratory analysis was car-
ried out centrally at the National Influenza Reference 
Laboratory, as defined in the National Contingency 
Plan for an Influenza Pandemic [8].
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After the beginning of the pandemic, and to cope with 
the increasing number of diagnoses requested by the 
National Health System, the Portuguese Laboratory 
Network for the Diagnosis of Influenza was activated 
[9]. This Network had originally been established in 
2006 with eight laboratories involved [10], after the 
emergence of human cases of influenza A(H5) virus 
infection, with the purpose of supporting, at the 
national level, the laboratory diagnosis of infection by 
a new influenza pandemic virus, but was subsequen-
tially de-activated in the absence of zoonotic transmis-
sion of new emergent influenza viruses. In May 2009, 
professionals from these laboratories began training in 
molecular methodologies for detection of the new influ-
enza A(H1N1)pdm09 virus. In the following two months, 
additional laboratories were involved and by the end 
of July 2009, all 13 members of the Network were able 
to perform those methods. Since then, the information 
generated, particularly that concerning the detection 
and molecular characterisation of influenza viruses 
associated with severe disease, has been integrated 
into the National Influenza Surveillance Programme 
and improved the understanding of the influenza activ-
ity in Portugal. 
The National Influenza Reference Laboratory, which 
coordinates the Portuguese Laboratory Network for the 
Diagnosis of Influenza, also analysed and confirmed 
suspected cases of antiviral resistance. The major-
ity of globally circulating influenza A(H1N1)pdm09 
viruses during the two seasons were still sensitive to 
oseltamivir and zanamivir; oseltamivir-resistant influ-
enza A(H1N1)pdm09 strains were found only sporadi-
cally and were associated with the substitution H275Y 
in neuraminidase gene [11]. 
This study describes the influenza activity during 
the 2009/10 and 2010/11 influenza seasons, based 
on the information collected through the Portuguese 
Laboratory Network for the Diagnosis of Influenza.
Methods
Surveillance period 
The influenza period 2009/10 was epidemiologically 
different from a normal influenza winter season. For 
this reason, it was decided to consider as the 2009/10 
pandemic season the period from week 17, 2009 to 
week 20, 2010. This particular period was chosen 
because the first influenza-positive case attributed 
to influenza A(H1N1)pdm09 infection was observed in 
week 17, 2009. During the 2010/11 season the labora-
tory Network was active during the usual surveillance 
period between October and May (weeks 40, 2010 
through 20, 2011). 
All 13 laboratories reported cases during the pandemic 
2009/10 season. During the 2010/11 winter, only nine 
participated in the reporting of cases with respiratory 
disease.
The Portuguese Laboratory Network for 
the Diagnosis of Influenza Infection 
The Portuguese Laboratory Network for the Diagnosis 
of Influenza Infection is currently composed of 13 labo-
ratories from reference hospitals on mainland Portugal 
and the islands (Figure 1). 
The main objective of this Network during the 2009/10 
and 2010/11 influenza seasons was to carry out the 
laboratory diagnosis of influenza A(H1N1)pdm09 
infection requested by the National Health Service. 
Currently, diagnostic capabilities include detection not 
only of influenza A(H1N1)pdm09 virus but also influ-
enza B virus (six laboratories), influenza A(H1) and 
Figure 1
Laboratories of the Portuguese Laboratory Network for 
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(1) Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P.; (2) 
Hospital de Curry Cabral; (3) Centro Hospitalar de S. João, 
E.P.E.; (4) Hospitais da Universidade de Coimbra, E.P.E.; (5) ARS 
do Algarve, I.P. - Laboratório Regional de Saúde Pública Laura 
Ayres; (6) Hospital Central do Funchal, E.P.E.; (7) Hospital do 
Divino Espírito Santo de Ponta Delgada, E.P.E.; (8) Hospital de 
Santo Espírito de Angra do Heroísmo, E.P.E.; (9) Instituto de 
Medicina Molecular da Faculdade de Medicina da Universidade 
de Lisboa; (10) Centro Hospitalar Lisboa Norte, E.P.E.; (11) Centro 
Hospitalar Lisboa Central, E.P.E.; (12) Centro Hospitalar do Porto, 
E.P.E.; (13) Hospital do Espírito Santo de Évora, E.P.E.
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A(H3) seasonal viruses (four laboratories), and other 
infectious agents associated with respiratory disease: 
adenovirus, coronavirus, rhinovirus, respiratory syn-
cytial virus, metapneumovirus, parainfluenza virus, 
Haemophilus influenzae and Streptococcus pneumo-
niae (three laboratories). 
Cases and variables studied 
During the two seasons, ILI cases from hospital emer-
gency units as well as from other primary healthcare 
units, and hospitalised cases of severe acute respira-
tory infection (SARI), were reported through a common 
Internet-based database or by an Excel spreadsheet 
sent to the National Influenza Reference Laboratory. 
Published case definitions were applied [12]. The 
notification form included clinical and epidemiologi-
cal information, such as demographic data, signs and 
symptoms, underlying conditions and information on 
vaccination and antiviral therapy. 
Laboratory analysis
For laboratory diagnosis and further virological char-
acterisation, nasopharyngeal swabs, or combined 
nasopharyngeal/oropharyngeal swabs, were collected 
into a suitable transport medium. Different real-time 
RT-PCR methodologies and platforms were used within 
the Network for the laboratory diagnosis of influenza 
infection.
Upon request from the Network, the National Influenza 
Reference Laboratory performed additional diagnoses 
(typing, subtyping and lineage determination by real-
time PCR of other influenza viruses), viral isolation [13] 
and antigenic and genetic characterisation of viral iso-
lates, according to the procedures adopted from the 
manual for the laboratory diagnosis and virological 
surveillance of influenza published by the World Health 
Organisation (WHO) [1] and adapted from the United 
States Centers for Disease Prevention and Control 
(CDC) [14]. 
Influenza virus isolates were characterised antigeni-
cally by haemagglutination inhibition tests (HAI) using 
antisera and reference virus strains distributed by the 
WHO Collaborating Centre in Atlanta. Selected isolates 
were sent to the WHO Collaborating Centre in London 
for further study. Genetic analysis of isolates was car-
ried out by sequencing the haemagglutinin (HA) gene 
encoding the HA1 subunit, using primer sequences 
available from CDC [14], for a subset of approximately 
25% of isolates encompassing the beginning, middle 
and end of each season. Sequences are available from 
the GenBank database. Phylogenetic analysis was 
performed with MEGA Software [15]. HA1 sequences 
from reference strains used in the genetic analysis 
were obtained from the EpiFlu database of the Global 
Initiative on Sharing Avian Influenza Data (GISAID) 
(Table 1).
The detection of antiviral resistance was performed 
by phenotypical assays, such as the neuraminidase 
inhibition assay, and by neuraminidase gene sequenc-
ing [1,14].
Statistical analysis
The probability of occurrence of an influenza case in 
the presence of the signs/symptoms considered for 
definition of ILI was estimated by calculating the indi-
vidual crude odds ratios, and the respective 95% con-
fidence intervals, of reporting each sign/symptom in 
both influenza cases (laboratory-confirmed) and ILI 
cases (influenza-negative result). 
Results
2009/10 season
In Portugal, a total of 62,089 ILI cases were reported 
through the Laboratory Network during the 2009/10 
pandemic season. Two peaks were observed, one 
occurring towards the end of the summer 2009 and 
another during November and December of the same 
year (Figure 2). 
The first case of influenza A(H1N1)pdm09 infection in 
Portugal was detected during week 17, 2009, when 
seasonal influenza viruses, linked to the previous 
winter season, were still circulating. A total of 25,985 
laboratory-confirmed influenza cases were found, over 
99% of which were associated with the new pandemic 
strain A(H1N1)pdm09. Other influenza viruses were 
also found: 190 non-subtyped influenza A viruses, 15 
seasonal influenza A(H1) viruses, 10 influenza A(H3) 
and 31 influenza B viruses. A first peak in influenza 
cases was observed during week 33 with 1,145 influ-
enza A(H1N1)pdm09 cases (45.9% of all ILI cases noti-
fied in week 33). Most of the cases during the first 
wave were detected in the south of Portugal and in the 
main urban areas (Lisbon and Oporto). The first wave 
was followed by a second wave with cases all over the 
country (mainland and islands) and with a peak dur-
ing week 46 with 3,266 influenza A(H1N1)pdm09 cases 
(60.2% of all ILI cases notified in week 46). 
Although the majority of notifications occurred in 
the population with 15 to 44 years of age (n=21,267; 
34.3% of all ILI cases), the highest proportion of influ-
enza-positive results was observed in children aged 
between five and 14 years (n=10,093; 38.8% of all 
influenza A(H1N1)pdm09-positive cases) (Table 2). The 
lowest number of reported cases (n=1,095; 1.8%) and 
influenza-positive results (n=515; 2.0%) were reported 
in the elderly. The highest proportion of influenza 
A(H1N1)pdm09-positive results within any one age 
group (64.0%) was observed in children aged 5–14 
years.
Eighty influenza strains were isolated and antigeni-
cally characterised, 43 of which were also geneti-
cally analysed (HA gene). The 80 influenza A(H1N1)
pdm09 strains isolated were antigenically homoge-
neous and showed high similarity with influenza A/
California/7/2009 (strain included in the pandemic 
4 www.eurosurveillance.org
ta
bl
e 
1
O
rig
in
 o
f t
he
 h
ae
m
ag
gl
ut
in
in
 se
qu
en
ce
s o
f i
nf
lu
en
za
 A
(H
1N
1)
pd
m
09
 is
ol
at
es
 u
se
d 
fo
r t
he
 p
hy
lo
ge
ne
tic
 a
na
ly
sis
Se
gm
et
n 
ID
Se
gm
en
t
Co
un
tr
y
Co
lle
ct
io
n 
da
te
Is
ol
at
e 
na
m
e
O
rig
in
at
in
g 
la
bo
ra
to
ry
Su
bm
itt
in
g 
la
bo
ra
to
ry
Au
th
or
s
EP
I2
15
95
7
H
A
Uk
ra
in
e
20
09
-O
ct
-2
7
A/
Lv
iv
/N
6/
20
09
M
in
is
tr
y 
of
 H
ea
lth
 o
f U
kr
ai
ne
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I3
01
77
9
H
A
Sw
ed
en
20
10
-D
ec
-1
2
A/
St
oc
kh
ol
m
/1
4/
20
10
Sw
ed
is
h 
In
st
itu
te
 fo
r I
nf
ec
tio
us
 D
is
ea
se
 
Co
nt
ro
l
Sw
ed
is
h 
In
st
itu
te
 fo
r I
nf
ec
tio
us
 D
is
ea
se
 
Co
nt
ro
l
EP
I3
19
59
0
H
A
20
11
-F
eb
-2
8
A/
As
tr
ak
ha
n/
1/
20
11
W
HO
 N
at
io
na
l I
nf
lu
en
za
 C
en
tr
e
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I3
19
45
9
H
A
Es
to
ni
a
20
11
-F
eb
-1
1
A/
Es
to
ni
a/
54
37
5/
11
He
al
th
 P
ro
te
ct
io
n 
In
sp
ec
to
ra
te
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I3
19
52
4
H
A
Ita
ly
20
11
-Ja
n-
11
A/
Tr
ie
st
e/
11
/2
01
1
Is
tit
ut
o 
Su
pe
rio
re
 d
i S
an
ità
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I3
19
43
4
H
A
Be
lg
iu
m
20
11
-Ja
n-
01
A/
Br
us
se
ls
/S
00
04
/2
01
1
Sc
ie
nt
ifi
c 
In
st
itu
te
 o
f P
ub
lic
 H
ea
lth
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I3
09
67
1
H
A
Fr
an
ce
20
10
-D
ec
-3
0
A/
Pa
ris
/2
30
1/
20
10
In
st
itu
t P
as
te
ur
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I3
19
52
7
H
A
Ru
ss
ia
20
11
-F
eb
-1
4
A/
St
. P
et
er
sb
ur
g/
27
/2
01
1
W
HO
 N
at
io
na
l I
nf
lu
en
za
 C
en
tr
e
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I3
20
14
1
H
A
Ru
ss
ia
20
11
-M
ar
-1
4
A/
St
. P
et
er
sb
ur
g/
10
0/
20
11
Ru
ss
ia
n 
Ac
ad
em
y 
of
 M
ed
ic
al
 S
ci
en
ce
s
Ce
nt
er
s 
fo
r D
is
ea
se
 C
on
tr
ol
 a
nd
 P
re
ve
nt
io
n
EP
I3
01
90
0
H
A
Ge
rm
an
y
20
10
-D
ec
-2
7
A/
Ba
de
n-
W
ur
tt
em
be
rg
/1
4/
20
10
Ro
be
rt
 K
oc
h 
In
st
itu
te
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I3
09
64
3
H
A
Un
ite
d 
Ki
ng
do
m
20
10
-D
ec
-3
1
A/
En
gl
an
d/
37
5/
20
10
Ce
nt
re
 fo
r I
nf
ec
tio
ns
, H
ea
lth
 P
ro
te
ct
io
n 
Ag
en
cy
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I3
19
60
7
H
A
Un
ite
d 
Ki
ng
do
m
20
10
-D
ec
-1
6
A/
En
gl
an
d/
67
6/
20
10
Ce
nt
re
 fo
r I
nf
ec
tio
ns
, H
ea
lth
 P
ro
te
ct
io
n 
Ag
en
cy
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I3
09
68
3
H
A
Sl
ov
en
ia
20
11
-Ja
n-
10
A/
Sl
ov
en
ia
/1
67
/2
01
1
La
bo
ra
to
ry
 fo
r V
iro
lo
gy
, N
at
io
na
l I
ns
tit
ut
e 
of
 P
ub
lic
 H
ea
lth
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I2
78
60
7
H
A
Ne
w
 
Ze
al
an
d
20
10
-Ju
l-1
2
A/
Ch
ris
tc
hu
rc
h/
16
/2
01
0
Ca
nt
er
bu
ry
 H
ea
lth
 S
er
vi
ce
s
W
HO
 C
ol
la
bo
ra
tin
g 
Ce
nt
re
 fo
r R
ef
er
en
ce
 a
nd
 
Re
se
ar
ch
 o
n 
In
flu
en
za
De
ng
 Y
-M
, I
an
ne
llo
 P
, 
Ca
ld
w
el
l N
, L
ea
ng
 S
-K
, 
Ko
m
ad
in
a 
N
EP
I2
79
89
5
H
A
Ho
ng
 K
on
g
20
10
-Ju
l-1
6
A/
Ho
ng
 K
on
g/
22
12
/2
01
0
Go
ve
rn
m
en
t V
iru
s 
Un
it
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I2
79
89
7
H
A
Ho
ng
 K
on
g
20
10
-Ju
l-1
6
A/
Ho
ng
 K
on
g/
22
13
/2
01
0
Go
ve
rn
m
en
t V
iru
s 
Un
it
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I3
01
39
9
H
A
20
10
-D
ec
-0
1
A/
Al
bo
rz
/5
60
7/
20
10
Te
hr
an
 U
ni
ve
rs
it
y 
of
 M
ed
ic
al
 S
ci
en
ce
s
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I3
19
50
3
H
A
M
ol
do
va
20
11
-F
eb
-0
7
A/
M
ol
do
va
/4
48
/2
01
1
Na
tio
na
l C
en
tr
e 
fo
r P
re
ve
nt
iv
e 
M
ed
ic
in
e
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I3
31
04
8
H
A
Fr
an
ce
20
11
-F
eb
-2
2
A/
To
ul
on
/1
17
3/
20
11
CR
R 
vi
ru
s 
In
flu
en
za
 re
gi
on
 S
ud
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I3
19
44
7
H
A
Cz
ec
h 
Re
pu
bl
ic
20
11
-Ja
n-
18
A/
Cz
ec
h 
Re
pu
bl
ic
/3
2/
20
11
Na
tio
na
l I
ns
tit
ut
e 
of
 P
ub
lic
 H
ea
lth
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I3
19
43
0
H
A
Al
ge
ria
20
10
-D
ec
-2
1
A/
Al
ge
ria
/G
38
8/
20
10
In
st
itu
t P
as
te
ur
 d
'A
lg
er
ie
Na
tio
na
l I
ns
tit
ut
e 
fo
r M
ed
ic
al
 R
es
ea
rc
h
EP
I1
78
50
7
H
A
Un
ite
d 
Ki
ng
do
m
20
09
-A
pr
-2
8
A/
En
gl
an
d/
19
5/
20
09
W
HO
 N
at
io
na
l I
nf
lu
en
za
 C
en
tr
e,
 N
at
io
na
l 
In
st
itu
te
 o
f M
ed
ic
al
 R
es
ea
rc
h 
(N
IM
R)
EP
I2
53
70
5
H
A
Ge
rm
an
y
20
09
-Ja
n-
01
A/
Ba
ye
rn
/6
9/
20
09
Ro
be
rt
 K
oc
h 
In
st
itu
te
Ro
be
rt
 K
oc
h-
In
st
itu
te
Bi
er
e 
B;
 S
ch
w
ei
ge
r B
EP
I1
79
60
5
H
A
Ne
w
 
Ze
al
an
d
20
09
-A
pr
-2
5
A/
Au
ck
la
nd
/3
/2
00
9
Au
ck
la
nd
 H
os
pi
ta
l
W
HO
 C
ol
la
bo
ra
tin
g 
Ce
nt
re
 fo
r R
ef
er
en
ce
 a
nd
 
Re
se
ar
ch
 o
n 
In
flu
en
za
EP
I2
47
24
5
H
A
Un
ite
d 
St
at
es
20
10
-F
eb
-1
1
A/
Ca
lif
or
ni
a/
04
/2
01
0
Ca
lif
or
ni
a 
De
pa
rt
m
en
t o
f H
ea
lth
 S
er
vi
ce
s
Ce
nt
er
s 
fo
r D
is
ea
se
 C
on
tr
ol
 a
nd
 P
re
ve
nt
io
n
EP
I1
76
62
0
H
A
Un
ite
d 
St
at
es
20
09
-A
pr
-0
9
A/
Ca
lif
or
ni
a/
07
/2
00
9
Ce
nt
er
s 
fo
r D
is
ea
se
 C
on
tr
ol
 a
nd
 P
re
ve
nt
io
n
5www.eurosurveillance.org
Figure 2
Figure 2. Weekly distribution of influenza-like illness and influenza A(H1N1)pdm09-positive cases, Portugal, 2009/10 and 
2010/2011 seasons (n=63,585)
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vaccine of the season) and with the later pandemic 
influenza A(H1N1) viruses A/Bayern/69/2009 and A/
Lviv/N6/2009 (data not shown).
All sequenced HA1 segments from 2009/10 isolates 
were similar to influenza A/California/7/2009 (Figure 
3). Compared to the vaccine strain, with the exception 
of influenza A/Lisboa/31/2009 and A/Lisboa/35/2009, 
all isolates contained the P83S amino acid substitu-
tion and grouped into clade 7 (S203T substitution in 
the Ca antibody binding site of HA1), described in the 
literature early in the pandemic [16]. Additional muta-
tions were found in the HA1 antigenic sites: G170R 
(A/Lisboa/65/2009), R205K (A/Lisboa/73/2009), 
D222E (observed in 18 isolated viruses) and S74G 
(A/Lisboa/171/2009). The sequences are available 
from GenBank with the following accession num-
bers: CY067801, CY067804, CY067807, CY067810, 
CY067819, CY067822, CY067825, CY067828, CY067831, 
CY067834, CY067837, CY067840, CY067843, 
CY067846, CY067849, CY067852, CY067855, 
CY067858, CY067861, CY067864, CY067867, CY067870, 
CY067873, CY067876, CY067879, CY067882, 
CY067885, CY067888, CY067891, CY067894, 
CY067897, CY067900, CY067903, CY067906, 
CY067909, CY067912, CY067915, CY067918, CY067765, 
CY067789, CY067792, CY067795, CY067798.
The amino acid substitution H275Y associated with 
oseltamivir resistance was found in the neuraminidase 
of one strain (A/Lisboa/171/2009), which was proved to 
be resistant by phenotypic assays. 
2010/11 season
Nine laboratories reported a total of 1,512 ILI cases, 
from week 40, 2010 to week 16, 2011, with a peak of 
236 cases (15.6%) observed in week 3, 2011. Influenza 
A(H1N1)pdm09 was tested for in 1,496 cases, 572 
(38.2%) of which were positive. The peak of labora-
tory-confirmed A(H1N1)pdm09-associated cases was 
also registered in week 3 of 2011 (n=87; 37.3% of all ILI 
cases notified in week 3). 
The majority of notifications (n=637; 42.6% of all ILI 
cases) and the higher proportion of influenza A(H1N1)
pdm09 cases (n=286, 50.0% of all positive results) 
occurred in the population between 15 and 44 years 
of age (Table 2). The lowest number of reported cases 
(n=47; 3.1%) and pandemic influenza-positive results 
(n=19; 3.3%) were reported in children aged 5 to 14 
years. The higher proportion of influenza A(H1N1)
pdm09-positive results within an age group was 
observed in older children and adults (15–44 years: 
44.9%; 45–64 years: 43.0%).
Following a single request from the Network in that 
season for additional characterisation at the National 
Influenza Reference Laboratory, the HA1 nucleotide 
sequence of one influenza A(H1N1)pdm09 detected in a 
clinical specimen was determined (Figure 3). This virus 
clustered in the genetic clade of A/Astrakhan/1/2011, 
one of four genetic clades circulating in Portugal dur-
ing the 2010/11 season (data not shown), and contained 
the P83S, I321V and S203T amino acid substitutions 
common to all 14 viruses analysed in that season, and 
the substitutions D97N, R205K, I216V and V249L char-
acteristic of the A/Astrakhan/1/2011 group. This virus 
also presented the H275Y mutation in the neuramini-
dase, associated with oseltamivir resistance.
From the clinical symptoms analysed, fever was the 
one that revealed a higher risk of being observed in an 
influenza case (crude OR: 3.3; 95% CI: 1.3–8.0) (Table 
3). 
Three laboratories also performed the differential 
diagnosis of respiratory infection in 284 cases, 12.7% 
of which were positive for other infectious agents (one 
adenovirus, three coronaviruses, one human metap-
neumovirus, 12 rhinoviruses, nine respiratory syncytial 
table 2
Distribution of influenza A(H1N1)pdm09 cases, by age group, Portugal, 2009/10 and 2010/11 seasons (n=63,585)
Age group
(years)
2009/10 2010/11
Number of cases Influenza A(H1N1)pdm09(% positive within the age group) Number of cases
a Influenza A(H1N1)pdm09
(% positive within the age group)
0-4 15,189 4,042 (26.6%) 192 48 (25.0%)
5-14 15,765 10,093 (64.0%) 47 19 (40.4%)
15-44 21,267 9,216 (43.3%) 637 286 (44.9%)
45-64 6,132 1,831 (29.9%) 402 173 (43.0%)
≥65 2,641 288 (10.9%) 207 41 (19.8%)
Information unavailable 1,095 515 (47.0%) 11 5 (45.5%)
Total 62,089 25,985 (41.9%) 1,496 572 (38.2%)
a  Although 1,512 cases were reported in 2010/11, only 1,496 were tested for influenza A(H1N1)pdm09. h.
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virus, one H. influenzae, one S. pneumoniae and seven 
mixed infections).
Discussion
Facing the circulation of a new influenza A(H1N1)pdm09 
virus and the potential threat to the population and the 
healthcare system, and the resulting increased aware-
ness and diagnostic requirements, the total number of 
ILI cases reported and analysed in our country during 
the 2009/10 winter was much higher than in previous 
influenza seasons. Cases with laboratory-confirmed 
diagnosis for influenza A(H1N1)pdm09 increased 
mainly due to wide sampling criteria and to rapid diag-
nostic tests. 
Given the considerable number of diagnoses per-
formed in different settings, both in primary care 
and hospitals, the Laboratory Network has made an 
important contribution to improve the surveillance of 
influenza activity in Portugal. Regarding the pattern 
of disease, the data collected through the Laboratory 
Network support the data obtained from the National 
Influenza Surveillance Programme [7] and suggest 
that the 2009/10 pandemic was similar to the previous 
influenza season in intensity and geographical dis-
tribution. Seasonal viruses were replaced by the new 
influenza A(H1N1)pdm09 strain, which caused disease 
particularly in young children, consistent with the data 
from all European countries where children under the 
age of 14 years were affected the most [5].
Using the data generated from the Laboratory Network 
it was possible to better characterise the beginning of 
the pandemic season, as the early cases were mainly 
reported to the reference hospitals, dedicated to the 
isolation of patients in an attempt to contain the virus 
and contribute to the management of the infection, 
as defined in the National Contingency Plan for an 
Influenza Pandemic [8]. During the mitigation phase of 
the pandemic, when the new pandemic strain had dis-
seminated throughout the world, both the Laboratory 
Network and the National Influenza Surveillance 
Programme contributed to the clinical, epidemiological 
and virological characterisation of the infection. 
The pandemic season was characterised by two waves, 
one in the summer and another during the winter. A 
very similar pattern was observed in Spain and other 
European countries [5,17]. In Portugal the pandemic 
influenza A(H1N1)pdm09 virus was first detected on 4 
May, soon after the first case confirmed in Spain (27 
April 2009) and in Europe (13 April 2009). Data from 
Spain and combined data for Europe show the first peak 
of influenza cases in 2009 during weeks 31 and 30, and 
the second peak during weeks 47 and 46, respectively 
[5,17]. The 2009 pandemic was considered a mild one 
for Europe, with little impact on services outside the 
health sector [5]. 
In the 2010/11 season, the first post-pandemic sea-
son, the number of laboratory diagnosis requests 
Figure 3
Maximum likelihood phylogenetic tree of HA1 nucleotide 
sequences from influenza A(H1N1)pdm09 viruses, 
Portugal, 2009/10 and 2010/2011 seasons (n=44). 
The 43 strains and amino acid substitutions from the 2009/10 
pandemic season are represented in red. The virus detected 
in a clinical specimen from the 2010/11 season is represented 
in green. The other 14 viruses detected in clinical specimens, 
which were circulating in Portugal during the 2010/11 season 
(data from the National Influenza Surveillance Programme), 
and amino acid substitutions found are represented in blue. 
Reference strains (obtained from GISAID`s EpiFlu database) are 
in black and the vaccine strain is underlined;  indicates cases 
with fatal outcome.  indicates cases vaccinated at least 14 
days before onset of symptoms. Bootstrap values above 50 are 
shown (500 replicates).
 A/Lisboa/51/2009 
 A/Lisboa/58/2009 
 A/Lisboa/89/2009 
 A/Lisboa/172/2009   † 
 A/Lisboa/86/2009 
 A/Lisboa/81/2009 
 A/Lisboa/82/2009 
 A/Lisboa/88/2009 
 A/Lisboa/79/2009 
 A/Algeria /G388/2010 
 A/Czech  Republic /32/2011 
 A/Lisboa/59/2009 
 A/Toulon/1173/2011  
 A/Moldova/448/2011  
 A/Alborz /5607/2010 
 EE53 
 A/Lisboa/61/2009 
 A/Lisboa/84/2009 
 A/Hong Kong/2212/2010  
 A/Hong Kong/2213/2010  
 A/Christchurch/16/2010  
 A/Lisboa/6/2010 
 SU83   
 SU347   
 SU44+ 
 A/Slovenia/167/2011  
 SU421   
 A/Lisboa/1/2011  
 A/St. Petersburg  /27/2011 
 EE221 
 A/England/676/2010  
 A/England/375/2010  
 A/Baden-Wurttenberg/14/2010  
 A/St. Petersburg /100/2011 
 A/Paris/2301/2010  
 A/Brussels/S0004/2011  
 A/Lisboa/74/2009 
 A/Lviv/N6/2009 
 A/Lisboa/71/2009 
 A/Lisboa/75/2009 
 A/Lisboa/34/2009 
 A/Lisboa/29/2009 
 A/Lisboa/57/2009 
 VIR1204918 ( H275Y ) 
 EE235   
 A/Trieste/11/2011  
 A/Estonia/54375/2011  
 EE194 
 A/Astrakhan/1/2011  
 SU497 
 SU364 
 SU252   
 A/Stockholm /14/2010 
 SU410   
 A/Lisboa/73/2009 
 A/Lisboa/65/2009 
 A/Lisboa/171/2009 (H275Y ) 
 A/Lisboa/2/2010    
 A/Lisboa/77/2009 
 A/Lisboa/80/2009 
 A/Lisboa/72/2009 
 A/Lisboa/70/2009 
 A/Lisboa/62/2009 
 A/Lisboa/60/2009 
 A/Lisboa/85/2009 
 A/Lisboa/66/2009 
 A/Lisboa/162/2009 
 A/Lisboa/78/2009 
 A/Lisboa/83/2009 
 A/Lisboa/108/2009   † 
 A/Lisboa/76/2009 
 A/Lisboa/63/2009 
 A/Lisboa/87/2009   † 
 A/Lisboa/69/2009 
 A/Lisboa/67/2009 
 A/Lisboa/68/2009 
 A/Lisboa/64/2009 
 A/England/195/2009  
 A/Auckland/3/2009 
 A/Lisboa/31/2009 
 A/Bayern/69/2009 
 A/Lisboa/35/2009 
 A/California/4/2009 
 A/California/07/2009 
98 
52 
53 
96 
81 
90 
78 
38 
86 
83 
86 
60 
70 
79 
37 
64 
61 
67 
51 
50 
40 
57 
39 
26 
40 
27 
50 
85 
0,001 
D222E
P83S
I321V
D97N
R205K
I216V
V249L
S203T
S185T
D97N
A134T
S183P
N125D
8 www.eurosurveillance.org
dramatically decreased due to tighter criteria for sam-
pling, although the actual ILI incidence rates were in 
the same order of magnitude as in the two previous 
seasons. The highest incidence rates for the seasons 
2008/09, 2009/10 and 2010/11 were 199.5, 133.7 and 
121.1 cases per 100,000 inhabitants, respectively 
[7]. Hence, the 41-fold difference in reporting cases 
between the pandemic and post-pandemic season, as 
seen in the data from the Laboratory Network, is due 
to the dramatic reduction in requests for diagnostics. 
The Network being a non-sentinel component of the 
National Influenza Surveillance Programme and inac-
tive before the start of the 2009 pandemic, 2008/09 
data for comparison are not available.
According to the National Influenza Surveillance 
Programme, the influenza A (H1N1)pdm09 continued 
to circulate in the 2010/11 season as the predominant 
virus, but co-circulating with influenza B viruses [18,19]. 
In Portugal, influenza B viruses were detected earlier 
in that season, in contrast to what was observed in 
Europe [18]. The circulation of influenza A(H1N1)pdm09 
virus occurred during the expected period without off-
season peaks, but the peak of the 2010/11 season was 
registered by the Laboratory Network three weeks later 
than the peak observed by the sentinel surveillance 
system within the National Influenza Surveillance 
Programme (week 52, 2010, data not shown), which 
was in agreement with what was observed in Spain 
and the rest of Europe at that time [20]. 
The age group of 5–14 year-old children was most 
affected by A(H1N1)pdm09-associated influenza in 
2009/10, as was also observed in Europe [21,22]. 
However, in the 2010/11 season, the highest percent-
age of A(H1N1)pdm09-influenza positive cases was 
found in a broader age range, from 15 to 64 years. This 
was in agreement with what was observed in Austria 
and Norway, but in contrast to other European coun-
tries where the most affected age group were children 
under 15 years of age [19].
In the 2009/10 pandemic season, cough and contact 
with another influenza patients were strongly associ-
ated with confirmed A(H1N1)pdm09 influenza, whereas 
in 2010/11, fever was the symptom that showed a 
higher association with a positive case. These results 
were consistent with other findings for seasonal [23] 
and pandemic influenza [24], where fever and cough 
were in strong association with influenza disease. This 
information can be useful for an earlier and more accu-
rate diagnosis of influenza in order to maximise the 
effectiveness of antiviral therapy and to avoid unnec-
essary antibiotic use [23].
During the pandemic season, a genetically similarity of 
the strains in circulation with the A/California/7/2009 
vaccine strain was observed. Since the 2010/11 sea-
son, increased genetic variation has occurred among 
the pandemic A(H1N1)pdm09 viruses circulating in 
Portugal and in Europe [25]. The Portuguese viruses 
clustered into four different genetic clades from the 
eight genetic groups so far identified [26,27]. The 
majority of them clustered in genetic group 5 repre-
sented by the A/Astrakhan/1/2011 strain.
Despite this genetic variation among the circulating 
A(H1N1)pdm09, very little antigenic drift was observed 
over the two seasons, and isolates were closely related 
to the strain A/California/7/2009 included in the pan-
demic vaccine of the 2009/10 season and of the sea-
sonal influenza vaccine for the 2010/11 season.
During the two winter seasons, the Laboratory Network 
found two viruses with the H275Y amino acid substitu-
tion in neuraminidase that has been associated with 
table 3
Correlation between presence of symptoms/signs considered for clinical definition of influenza-like illness and influenza 
cases, Portugal, 2009/10 and 2010/11 seasons (n=63,585)
Sign/symptom
2009/10 2010/11
Positive cases (%) OR (crude) CI (95%) Positive cases (%) OR (crude) CI (95%)
Fever (≥38°C) 44.1 1.3 1.3–1.4 43.3 3.3 1.3–8.0
Cough 47.4 2.4 2.3–2.5 39.6 1.0 0.4–2.5
Sore throat 42.1 1.0 0.4–2.4 44.7 1.4 0.7–3.0
Respiratory difficulty 29.4 0.5 0.4–0.5 50.0 1.0 0.3–2.8
Contact with another influenza patient 63.6 3.6 3.1–4.1 NA NA NA
Myalgia 47.2 1.4 1.4–1.5 NA NA NA
Headache 50.4 1.8 1.8–1.9 NA NA NA
Sudden onset NA NA NA 40.0 1.1 0.6–2.3
CI: confidence interval; NA: not applicable; OR: odds ratio.
The symptoms/signs that revealed an elevated risk of being observed in an influenza case are represented in bold. Number of ILI cases 
reporting information differed for each sign/symptom; only valid records (reporting presence or absence of signs/symptoms and with a 
valid laboratory result) were considered in the calculation of individual crude odds ratios. The presence of a sign/symptom is compared 
between an ILI case and an influenza case.
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oseltamivir resistance. Globally, a limited number of 
sporadic oseltamivir-resistant cases of A(H1N1)pdm09 
have been reported [11,28], but the majority of circu-
lating influenza A(H1N1)pdm09 viruses were sensitive 
to neuraminidase inhibitors [11]. The two Portuguese 
H275Y viruses were detected in immunocompromised 
patients under oseltamivir treatment: one was con-
firmed resistant to oseltamivir by phenotypic assays 
(2009/10 season); the other came from a case of 
severe influenza with fatal outcome (2010/11 season), 
but confirmation by phenotypic assays could not be 
done since the virus was not isolated. The monitoring 
of antiviral resistance was, and continues to be, essen-
tial since antiviral treatment is an important tool in the 
clinical management of severe or complicated influ-
enza cases [7, 11].
During 2010/11 the Network also increased the diag-
nostic capability by implementing methodologies for 
the detection of other respiratory pathogens, having 
found several other agents associated with ILI co-circu-
lating with influenza. This information can be a major 
contribution to a better understanding of the epidemi-
ology of the disease.
Since September 2011 the Portuguese national health 
authorities have been developing and implementing an 
integrated surveillance system for SARI in five hospi-
tals members of the Portuguese Laboratory Network. 
In the near future, this surveillance system will hope-
fully be extended to other hospitals and we expect 
that the established Laboratory Network will play a 
major role. Continuous laboratory participation and 
further advances in diagnostic capacity are essential 
to improve the surveillance of respiratory infections in 
Portugal.
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